• Mashup Score: 0

    March 4, 2023 — The impact of statin use to prevent heart damage during a cancer patient’s chemotherapy was in focus during a late-breaking scientific session, on the STOP-CA Trial, presented at the American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC, being held March 4-6 in New Orleans, LA. In “Statins to Prevent the…

    Tweet Tweets with this article
    • @DAICeditor In the #STOP_CA Trial researchers found that among people receiving chemotherapy regimens containing #anthracyclines for #lymphoma, those who took #atorvastatin for one year were significantly less likely to show evidence of #heartdysfunction: https://t.co/Y515xvA4nT

  • Mashup Score: 6

    This randomized clinical trial evaluates 3-year event-free survival and overall survival of an anthracycline-free and anthracycline-containing regimen with dual ERBB2 blockade in patients with stage II and III ERBB2-positive breast cancer.

    Tweet Tweets with this article
    • Survival results from #TRAIN2 on omitting #anthracyclines in women with #HER2+ early #BreastCancer presented at #ASCO20 now published in @JAMAOnc: caution needed considering the #chemotherapy backbone of the experimental arm https://t.co/zLzcNam1UY @OncoAlert @JAMANetwork #bcsm

  • Mashup Score: 0

    2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.

    Tweet Tweets with this article
    • TRAIN-2 results confirm no benefit with #anthracyclines as neoadjuvant treatment in patients with stage II/III HER2-positive #breastcancer. EFS and OS were similar with and without anthracyclines. Abstract 501, https://t.co/ZNM0sFIoLZ #ASCO2020 #ASCO20 #bcsm https://t.co/D6EHTcMVCL